|
Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid. It is a manufactured form of human insulin; where a single amino acid has been exchanged. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream. As a result, it starts working in minutes, which allows one to take insulin and eat right away. Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus. Novolog allows for a flexible dosing schedule, which allows patients to adjust their insulin according to any changes in their eating habits.〔(【引用サイトリンク】title=Novolog: most FAQ )〕 The safety and efficacy of insulin aspart (NovoLog/NovoRapid) in real-life clinical practice was evaluated in the A1chieve study. It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. This analog has increased charge repulsion, which prevents the formation of hexamers, to create a faster-acting insulin. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor. According to JDRF, insulin aspart was approved for marketing in the United States by the Food and Drug Administration in June 2000. == Chemical properties == The components of insulin aspart are as follows: * Metal ion – zinc (19.6 μg/mL) * Buffer – disodium hydrogen phosphate dihydrate (1.25 mg/mL) * Preservatives – m-cresol (1.72 mg/mL) and phenol (1.50 mg/mL) * Isotonicity agents – glycerin (16 mg/mL) and sodium chloride (0.58 mg/mL). The pH of insulin aspart is 7.2–7.6.〔Crommelin DJA, Sindelar RD, Meibohm B. 2008. Pharmaceutical Biotechnology: Fundamentals and Applications. New York, NY: Informa Healthcare USA, Inc. p 270.〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Insulin aspart」の詳細全文を読む スポンサード リンク
|